Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.2.9159.3719
Address
Level 4 309 George Street Sydney, New South Wales (NSW) 2000
Description
EchoIQ Ltd. engages in the development and application of artificial intelligence for the cardiac diagnostics sector, as well as the supply of software used by the health fund and insurance sector. It operates through the Houston WeHave Software and Echo IQ segments. The Houston WeHave Software segment offers products and services across defence and other sectors. The Echo IQ segment focuses on developing artificial intelligence software that aids in predicting Aortic Stenosis heart condition. The company was founded by Richard Charles Anstey on March 31, 2010 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.1 - 0.32
Trade Value (12mth)
AU$106,383.00
1 week
8.93%
1 month
3.39%
YTD
32.61%
1 year
190.48%
All time high
3.03
EPS 3 yr Growth
0.90%
EBITDA Margin
%
Operating Cashflow
-$4m
Free Cash Flow Return
-55.50%
ROIC
-76.50%
Interest Coverage
N/A
Quick Ratio
1.60
Shares on Issue (Fully Dilluted)
568m
HALO Sector
Mining
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
14 March 25 |
mFund - Monthly Redemption Report - PML01 (PML-AU)
×
mFund - Monthly Redemption Report - PML01 (PML-AU) |
14 March 25 |
mFund - Monthly Redemption Report - PML02 (PML-AU)
×
mFund - Monthly Redemption Report - PML02 (PML-AU) |
07 March 25 |
Investor Webinar Presentation
×
Investor Webinar Presentation |
06 March 25 |
Investor Webinar
×
Investor Webinar |
06 March 25 |
Notification of cessation of securities - EIQ
×
Notification of cessation of securities - EIQ |
06 March 25 |
Notification regarding unquoted securities - EIQ
×
Notification regarding unquoted securities - EIQ |
06 March 25 |
Notification regarding unquoted securities - EIQ
×
Notification regarding unquoted securities - EIQ |
06 March 25 |
Notification regarding unquoted securities - EIQ
×
Notification regarding unquoted securities - EIQ |
06 March 25 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
05 March 25 |
Strong Progress in First Two Months of CY25 Achieved
×
Strong Progress in First Two Months of CY25 Achieved |
03 March 25 |
Proposed issue of securities - EIQ
×
Proposed issue of securities - EIQ |
27 February 25 |
Appendix 4D 31 December 2024
×
Appendix 4D 31 December 2024 |
27 February 25 |
Half Year Accounts 31 December 2024
×
Half Year Accounts 31 December 2024 |
12 February 25 |
$1.26M R&D TAX INCENTIVE RECEIVED
×
$1.26M R&D TAX INCENTIVE RECEIVED |
06 February 25 |
mFund - Monthly Redemption Report - PML01 (PML-AU)
×
mFund - Monthly Redemption Report - PML01 (PML-AU) |
06 February 25 |
mFund - Monthly Redemption Report - PML02 (PML-AU)
×
mFund - Monthly Redemption Report - PML02 (PML-AU) |
04 February 25 |
Notification of cessation of securities - EIQ
×
Notification of cessation of securities - EIQ |
31 January 25 |
Response to ASX Query Letter
×
Response to ASX Query Letter |
30 January 25 |
Quarterly Activities Report and Appendix 4C Cash Flow Report
×
Quarterly Activities Report and Appendix 4C Cash Flow Report |
14 January 25 |
Commencement of Chief Executive Officer
×
Commencement of Chief Executive Officer |
06 January 25 |
mFund - Monthly Redemption Report - PML01 (PML-AU)
×
mFund - Monthly Redemption Report - PML01 (PML-AU) |
06 January 25 |
mFund - Monthly Redemption Report - PML02 (PML-AU)
×
mFund - Monthly Redemption Report - PML02 (PML-AU) |
06 January 25 |
mFund - Distribution - PML01 (PML-AU)
×
mFund - Distribution - PML01 (PML-AU) |
06 January 25 |
mFund - Distribution - PML02 (PML-AU)
×
mFund - Distribution - PML02 (PML-AU) |
24 December 24 |
PRE-SUBMISSION MEETING WITH US FDA FOR HEART FAILURE
×
PRE-SUBMISSION MEETING WITH US FDA FOR HEART FAILURE |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.